Mobile Menu

2023 News



Media Inquiries

Drew Hoffman



April 13, 2023

Wheeler Bio Announces Closing of $31 Million Series A Round Supporting its Clinical (CGMP) Drug Substance Manufacturing Facility in Oklahoma City

Wheeler Bio, a CDMO specializing in therapeutic antibodies, has closed its Series A funding round, co-led by Charles River Laboratories and Echo. The firm's Portable CMC is an open-source middleware that enhances the gene-to-IND supply chain, delivering speed, efficiency, predictability, and freedom to operate. The firm intends to complete a 500L scale CGMP cell banking and drug substance manufacturing facility in Oklahoma City, with the first batches of production set to commence in Q3 2023. The new facility will utilize integrated tools and technologies like Solentim, Ambr Microbioreactors, and DynaDrive Single-Use Bioreactors.

Read More

April 5, 2023

Deka Biosciences Announces First-in-Human Dose in Phase 1 Clinical Trial of DK210 (EGFR)

Deka Biosciences has announced the dosing of the first subject in a Phase 1 clinical trial of DK210 (EGFR), a novel cytokine therapy for cancer and inflammatory diseases. The trial aims to evaluate the safety, potential efficacy, and biomarker responses of the therapy in patients with advanced solid cancer(s) expressing epidermal growth factor receptors. DK210 (EGFR) is the first of several DiakinesTM developed by Deka, which involves coupling two cytokines onto a single targeting system for enhanced precision and efficacy. The self-administered treatment is expected to provide patients with greater comfort and convenience.

Read More

January 30, 2023

Deka Biosciences Receives FDA Clearance of DK210 (EGFR) Investigational New Drug Application

Deka Biosciences ("Deka"), a biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the investigational new drug (IND) application for DK210 (EGFR) and concluded that Deka may proceed with a Phase 1 clinical trial in the United States.

Read More

Let’s build something great together.